This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NITE Nightstar Therapeutics (NITE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Nightstar Therapeutics Stock (NASDAQ:NITE) 30 days 90 days 365 days Advanced Chart Get Nightstar Therapeutics alerts:Sign Up Key Stats Today's Range$30.93▼$30.9350-Day Range$25.41▼$25.4152-Week Range$9.59▼$29.55Volume711 shsAverage Volume185,808 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom. Read More Receive NITE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nightstar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NITE Stock News HeadlinesKnight Therapeutics: Strong Revenue Growth and Strategic Prospects Justify Buy RatingNovember 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)November 9, 2024 | markets.businessinsider.comBanks aren’t ready for this altcoin—are you?Want to see why we believe this could be the next evolution of financial infrastructure? The old financial system is showing cracks—and this altcoin might be ready to take its placeJuly 2 at 2:00 AM | Crypto 101 Media (Ad)Knight Therapeutics price target lowered to C$6.25 from C$6.75 at StifelNovember 9, 2024 | markets.businessinsider.comWindtree Therapeutics $WINT Announces Positive Phase 2b Results In Early Cardiogenic Shock TreatmentOctober 7, 2024 | msn.comNITE The Nightview ETFSeptember 25, 2024 | seekingalpha.comThank you for supporting The Big Night InNovember 12, 2023 | bbc.co.ukBills vs. Giants Sunday Night Football highlights: Buffalo survives for late winNovember 1, 2023 | usatoday.comSee More Headlines NITE Stock Analysis - Frequently Asked Questions How were Nightstar Therapeutics' earnings last quarter? Nightstar Therapeutics PLC (NASDAQ:NITE) released its earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.13. When did Nightstar Therapeutics IPO? Nightstar Therapeutics (NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers. What other stocks do shareholders of Nightstar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nightstar Therapeutics investors own include Canopy Growth (CGC), Cronos Group (CRON), OncoMed Pharmaceuticals (OMED), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals (LGND), Neurocrine Biosciences (NBIX) and Sangamo Therapeutics (SGMO). Company Calendar Last Earnings11/13/2018Today7/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NITE CIK1711675 Webwww.nightstartx.com Phone44-20-7062-2777FaxN/AEmployees47Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.89% Return on Assets-27.65% Debt Debt-to-Equity RatioN/A Current Ratio8.54 Quick Ratio8.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.89 per share Price / Book5.25Miscellaneous Outstanding Shares33,540,000Free FloatN/AMarket Cap$1.04 billion OptionableNot Optionable Beta2.84 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:NITE) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Nightstar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.